HC Wainwright Issues Positive Forecast for Theravance Biopharma (NASDAQ:TBPH) Stock Price

Theravance Biopharma (NASDAQ:TBPH) had its target price boosted by HC Wainwright from $15.00 to $20.00 in a research report report published on Tuesday morning,Benzinga reports. The firm currently has a buy rating on the biopharmaceutical company’s stock.

Several other brokerages have also recently commented on TBPH. B. Riley initiated coverage on shares of Theravance Biopharma in a research report on Friday, September 12th. They issued a “buy” rating and a $28.00 target price for the company. Zacks Research cut shares of Theravance Biopharma from a “strong-buy” rating to a “hold” rating in a research note on Monday, September 15th. Weiss Ratings restated a “hold (c)” rating on shares of Theravance Biopharma in a research report on Wednesday, October 8th. Finally, Wall Street Zen raised Theravance Biopharma from a “hold” rating to a “strong-buy” rating in a report on Saturday, August 16th. Two equities research analysts have rated the stock with a Strong Buy rating, two have issued a Buy rating and two have assigned a Hold rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Buy” and a consensus target price of $24.25.

Theravance Biopharma Stock Performance

Shares of NASDAQ TBPH opened at $18.50 on Tuesday. The stock has a market capitalization of $931.66 million, a P/E ratio of 32.46 and a beta of 0.07. The stock’s fifty day moving average is $14.32 and its 200 day moving average is $12.20. Theravance Biopharma has a 52 week low of $7.90 and a 52 week high of $18.96.

Institutional Investors Weigh In On Theravance Biopharma

Hedge funds and other institutional investors have recently bought and sold shares of the company. Hillsdale Investment Management Inc. acquired a new position in Theravance Biopharma in the 3rd quarter worth about $4,536,000. Vanguard Group Inc. grew its holdings in shares of Theravance Biopharma by 2.5% during the third quarter. Vanguard Group Inc. now owns 2,211,582 shares of the biopharmaceutical company’s stock worth $32,289,000 after purchasing an additional 54,152 shares during the last quarter. JPMorgan Chase & Co. grew its holdings in shares of Theravance Biopharma by 78.3% during the third quarter. JPMorgan Chase & Co. now owns 213,104 shares of the biopharmaceutical company’s stock worth $3,111,000 after purchasing an additional 93,591 shares during the last quarter. Baader Bank Aktiengesellschaft acquired a new position in shares of Theravance Biopharma in the third quarter valued at approximately $781,000. Finally, State of Wyoming raised its holdings in Theravance Biopharma by 62.5% in the 3rd quarter. State of Wyoming now owns 30,752 shares of the biopharmaceutical company’s stock valued at $449,000 after buying an additional 11,824 shares during the last quarter. Institutional investors own 99.10% of the company’s stock.

About Theravance Biopharma

Theravance Biopharma, Inc is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small molecule drugs designed to better meet patient needs. Its research is focused in the areas of inflammation and immunology.
In pursuit of its purpose, Theravance Biopharma applies insights and innovation at each stage of its business and utilizes its internal capabilities and those of partners around the world.